Globus Medical, Inc. (GMED)
NYSE: GMED · IEX Real-Time Price · USD
68.05
+0.13 (0.19%)
Jul 2, 2024, 4:00 PM EDT - Market closed
Globus Medical Stock Forecast
Stock Price Forecast
The 10 analysts with 12-month price forecasts for Globus Medical stock have an average target of 69.4, with a low estimate of 53 and a high estimate of 85. The average target predicts an increase of 1.98% from the current stock price of 68.05.
Analyst Consensus: Buy
* Price targets were last updated on May 29, 2024.
Analyst Ratings
The average analyst rating for Globus Medical stock from 11 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 4 | 4 | 4 | 4 |
| Buy | 2 | 2 | 2 | 2 | 3 | 3 |
| Hold | 7 | 4 | 4 | 4 | 4 | 4 |
| Sell | 1 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 13 | 9 | 10 | 10 | 11 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| BTIG | BTIG | Strong Buy Maintains $63 → $72 | Strong Buy | Maintains | $63 → $72 | +5.80% | May 29, 2024 |
| Piper Sandler | Piper Sandler | Hold → Buy Upgrades $60 → $80 | Hold → Buy | Upgrades | $60 → $80 | +17.56% | May 20, 2024 |
| Barclays | Barclays | Buy Maintains $83 → $85 | Buy | Maintains | $83 → $85 | +24.91% | May 9, 2024 |
| BTIG | BTIG | Strong Buy Maintains $60 → $63 | Strong Buy | Maintains | $60 → $63 | -7.42% | May 8, 2024 |
| Piper Sandler | Piper Sandler | Hold Maintains $55 → $60 | Hold | Maintains | $55 → $60 | -11.83% | May 8, 2024 |
Financial Forecast
Revenue This Year
2.52B
from 1.57B
Increased by 60.92%
Revenue Next Year
2.71B
from 2.52B
Increased by 7.25%
EPS This Year
2.88
from 1.07
Increased by 168.76%
EPS Next Year
3.38
from 2.88
Increased by 17.55%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 2.6B | 2.8B | 3.1B | 3.4B | 3.6B |
| Avg | 2.5B | 2.7B | 2.9B | 3.2B | 3.5B |
| Low | 2.4B | 2.6B | 2.7B | 2.9B | 3.4B |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 66.3% | 12.5% | 14.3% | 15.7% | 15.2% |
| Avg | 60.9% | 7.3% | 7.5% | 8.2% | 11.9% |
| Low | 53.4% | 1.3% | -1.0% | 0.2% | 7.5% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 3.01 | 3.92 | 4.67 | 5.02 | 5.42 |
| Avg | 2.88 | 3.38 | 4.00 | 4.67 | 5.26 |
| Low | 2.72 | 3.08 | 3.39 | 4.18 | 5.06 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 180.9% | 36.2% | 38.2% | 25.4% | 16.0% |
| Avg | 168.8% | 17.6% | 18.4% | 16.7% | 12.7% |
| Low | 154.6% | 7.0% | 0.3% | 4.5% | 8.2% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.